Ceftriaxone Dosing for Enteric Fever per Indian Guidelines
For uncomplicated enteric fever in India, ceftriaxone should be administered at 60-80 mg/kg/day (maximum 2-4 g/day) intravenously for 5-7 days in children, and 2 g once daily for 7 days in adults. 1
Pediatric Dosing
- Standard dose: 50-80 mg/kg/day IV once daily or in divided doses
- Maximum daily dose: 2-4 g/day
- Duration: 5-7 days for uncomplicated cases 1, 2
The WHO Pocket Book recommends 80 mg/kg daily for 5-7 days as second-line therapy when fluoroquinolones fail 1. However, clinical studies from India have successfully used 60-80 mg/kg/day for 5-7 days 3, and flexible-duration protocols (continuing until defervescence plus 5 additional days) have shown excellent efficacy 4.
Adult Dosing
- Standard dose: 2 g IV once daily
- Duration: 5-7 days for uncomplicated cases 2
The FDA label specifies that the usual adult dose is 1-2 grams once daily, with a maximum of 4 grams per day 2.
Critical Context for Indian Practice
Emerging ceftriaxone resistance is now documented in India, particularly from Maharashtra, with a 26.35% resistance rate reported in a 2025 outbreak from Thane 5. This represents a significant shift from historical patterns where ceftriaxone maintained near-universal susceptibility.
When to Use Ceftriaxone
Ceftriaxone remains appropriate as:
- Second-line therapy when fluoroquinolones are contraindicated or have failed 1, 6
- First-line empirical therapy in areas with high fluoroquinolone resistance (>10%) 6
- Definitive therapy once susceptibility is confirmed by culture 7
Important Caveats
Always obtain blood cultures before initiating therapy to guide treatment and detect resistance 6, 7. The clinical response to ceftriaxone is typically slower than fluoroquinolones, with mean fever clearance times of 4-5 days 4, 8, 3.
Do not use in neonates ≤28 days receiving calcium-containing IV solutions due to precipitation risk 2. In neonates requiring ceftriaxone, administer over 60 minutes (not 30 minutes as in older children) to reduce bilirubin encephalopathy risk 2.
Comparison with Alternatives
Recent evidence shows azithromycin (20 mg/kg/day for 5-7 days) may be superior to ceftriaxone, with lower relapse rates 9, 6. In regions with documented ceftriaxone resistance, azithromycin or carbapenems should be considered 5, 7.
Monitor for treatment failure if fever persists beyond 7 days, which may indicate resistance or complications requiring alternative therapy 10, 4.